These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 25312638)

  • 1. Relation of serum uric acid levels and outcomes among patients hospitalized for worsening heart failure with reduced ejection fraction (from the efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan trial).
    Vaduganathan M; Greene SJ; Ambrosy AP; Mentz RJ; Subacius HP; Chioncel O; Maggioni AP; Swedberg K; Zannad F; Konstam MA; Senni M; Givertz MM; Butler J; Gheorghiade M;
    Am J Cardiol; 2014 Dec; 114(11):1713-21. PubMed ID: 25312638
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Haemoconcentration, renal function, and post-discharge outcomes among patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial.
    Greene SJ; Gheorghiade M; Vaduganathan M; Ambrosy AP; Mentz RJ; Subacius H; Maggioni AP; Nodari S; Konstam MA; Butler J; Filippatos G;
    Eur J Heart Fail; 2013 Dec; 15(12):1401-11. PubMed ID: 23845795
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical profile and prognostic value of low systolic blood pressure in patients hospitalized for heart failure with reduced ejection fraction: insights from the Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST) trial.
    Ambrosy AP; Vaduganathan M; Mentz RJ; Greene SJ; Subačius H; Konstam MA; Maggioni AP; Swedberg K; Gheorghiade M
    Am Heart J; 2013 Feb; 165(2):216-25. PubMed ID: 23351825
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of arginine vasopressin levels with outcomes and the effect of V2 blockade in patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial.
    Lanfear DE; Sabbah HN; Goldsmith SR; Greene SJ; Ambrosy AP; Fought AJ; Kwasny MJ; Swedberg K; Yancy CW; Konstam MA; Maggioni AP; Zannad F; Gheorghiade M;
    Circ Heart Fail; 2013 Jan; 6(1):47-52. PubMed ID: 23239836
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sacubitril/valsartan reduces serum uric acid concentration, an independent predictor of adverse outcomes in PARADIGM-HF.
    Mogensen UM; Køber L; Jhund PS; Desai AS; Senni M; Kristensen SL; Dukát A; Chen CH; Ramires F; Lefkowitz MP; Prescott MF; Shi VC; Rouleau JL; Solomon SD; Swedberg K; Packer M; McMurray JJV;
    Eur J Heart Fail; 2018 Mar; 20(3):514-522. PubMed ID: 29193563
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The prognostic significance of heart rate in patients hospitalized for heart failure with reduced ejection fraction in sinus rhythm: insights from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study With Tolvaptan) trial.
    Greene SJ; Vaduganathan M; Wilcox JE; Harinstein ME; Maggioni AP; Subacius H; Zannad F; Konstam MA; Chioncel O; Yancy CW; Swedberg K; Butler J; Bonow RO; Gheorghiade M;
    JACC Heart Fail; 2013 Dec; 1(6):488-96. PubMed ID: 24622000
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial.
    Konstam MA; Gheorghiade M; Burnett JC; Grinfeld L; Maggioni AP; Swedberg K; Udelson JE; Zannad F; Cook T; Ouyang J; Zimmer C; Orlandi C;
    JAMA; 2007 Mar; 297(12):1319-31. PubMed ID: 17384437
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gender does not affect postdischarge outcomes in patients hospitalized for worsening heart failure with reduced ejection fraction (from the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan [EVEREST] Trial).
    Shah AN; Mentz RJ; Gheorghiade M; Kwasny MJ; Fought AJ; Zannad F; Swedberg K; Maggioni AP; Konstam MA
    Am J Cardiol; 2012 Dec; 110(12):1803-8. PubMed ID: 22999071
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rationale and design of the multicenter, randomized, double-blind, placebo-controlled study to evaluate the Efficacy of Vasopressin antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST).
    Gheorghiade M; Orlandi C; Burnett JC; Demets D; Grinfeld L; Maggioni A; Swedberg K; Udelson JE; Zannad F; Zimmer C; Konstam MA
    J Card Fail; 2005 May; 11(4):260-9. PubMed ID: 15880334
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in renal function during hospitalization and soon after discharge in patients admitted for worsening heart failure in the placebo group of the EVEREST trial.
    Blair JE; Pang PS; Schrier RW; Metra M; Traver B; Cook T; Campia U; Ambrosy A; Burnett JC; Grinfeld L; Maggioni AP; Swedberg K; Udelson JE; Zannad F; Konstam MA; Gheorghiade M;
    Eur Heart J; 2011 Oct; 32(20):2563-72. PubMed ID: 21785107
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in serum potassium levels during hospitalization in patients with worsening heart failure and reduced ejection fraction (from the EVEREST trial).
    Khan SS; Campia U; Chioncel O; Zannad F; Rossignol P; Maggioni AP; Swedberg K; Konstam MA; Senni M; Nodari S; Vaduganathan M; Subacius H; Butler J; Gheorghiade M;
    Am J Cardiol; 2015 Mar; 115(6):790-6. PubMed ID: 25728846
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum Osmolality and Postdischarge Outcomes After Hospitalization for Heart Failure.
    Vaduganathan M; Marti CN; Mentz RJ; Greene SJ; Ambrosy AP; Subacius HP; Fonarow GC; Chioncel O; Bazari H; Maggioni AP; Zannad F; Konstam MA; Sato N; Gheorghiade M; Butler J;
    Am J Cardiol; 2016 Apr; 117(7):1144-50. PubMed ID: 26851146
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum uric acid, influence of sacubitril-valsartan, and cardiovascular outcomes in heart failure with preserved ejection fraction: PARAGON-HF.
    Selvaraj S; Claggett BL; Pfeffer MA; Desai AS; Mc Causland FR; McGrath MM; Anand IS; van Veldhuisen DJ; Kober L; Janssens S; Cleland JGF; Pieske B; Rouleau JL; Zile MR; Shi VC; Lefkowitz MP; McMurray JJV; Solomon SD
    Eur J Heart Fail; 2020 Nov; 22(11):2093-2101. PubMed ID: 32840930
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial.
    Gheorghiade M; Gattis WA; O'Connor CM; Adams KF; Elkayam U; Barbagelata A; Ghali JK; Benza RL; McGrew FA; Klapholz M; Ouyang J; Orlandi C;
    JAMA; 2004 Apr; 291(16):1963-71. PubMed ID: 15113814
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relation of serum magnesium levels and postdischarge outcomes in patients hospitalized for heart failure (from the EVEREST Trial).
    Vaduganathan M; Greene SJ; Ambrosy AP; Mentz RJ; Fonarow GC; Zannad F; Maggioni AP; Konstam MA; Subacius HP; Nodari S; Butler J; Gheorghiade M;
    Am J Cardiol; 2013 Dec; 112(11):1763-9. PubMed ID: 24095030
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vasopressin V2 receptor antagonist tolvaptan is effective in heart failure patients with reduced left ventricular systolic function and low blood pressure.
    Suzuki S; Yoshihisa A; Yamaki T; Sugimoto K; Kunii H; Nakazato K; Abe Y; Saito T; Ohwada T; Suzuki H; Saitoh S; Kubota I; Takeishi Y;
    Int Heart J; 2015; 56(2):213-8. PubMed ID: 25740399
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical profile and prognostic value of anemia at the time of admission and discharge among patients hospitalized for heart failure with reduced ejection fraction: findings from the EVEREST trial.
    Mentz RJ; Greene SJ; Ambrosy AP; Vaduganathan M; Subacius HP; Swedberg K; Maggioni AP; Nodari S; Ponikowski P; Anker SD; Butler J; Gheorghiade M
    Circ Heart Fail; 2014 May; 7(3):401-8. PubMed ID: 24737459
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kidney Function, Nutritional Status, and the Left Ventricle Dysfunction Are Associated with Serum Uric Acid Levels in Patients with Heart Failure with Reduced Ejection Fraction.
    Owczarek AJ; Choręza P; Arabzada H; Chudek J; Wojnicz R
    Ann Clin Lab Sci; 2018 Sep; 48(5):608-613. PubMed ID: 30373865
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum uric acid is associated with mortality and heart failure hospitalizations in patients with complicated myocardial infarction: findings from the High-Risk Myocardial Infarction Database Initiative.
    von Lueder TG; Girerd N; Atar D; Agewall S; Lamiral Z; Kanbay M; Pitt B; Dickstein K; Zannad F; Rossignol P;
    Eur J Heart Fail; 2015 Nov; 17(11):1144-51. PubMed ID: 26424212
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic significance of serum total cholesterol and triglyceride levels in patients hospitalized for heart failure with reduced ejection fraction (from the EVEREST Trial).
    Greene SJ; Vaduganathan M; Lupi L; Ambrosy AP; Mentz RJ; Konstam MA; Nodari S; Subacius HP; Fonarow GC; Bonow RO; Gheorghiade M;
    Am J Cardiol; 2013 Feb; 111(4):574-81. PubMed ID: 23206923
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.